Publication in the BMJ of the Pilot Study on the cost-effectiveness of FreeO2 in patients with COPD acute exacerbations

25What  is the FreeO2 value proposition for COPD exacerbation ?

Minus 21% in hospital cost of care (at 180days).

Thomas G Poder1,2, Christian R C Kouakou2, Pierre-Alexandre Bouchard3, Véronique Tremblay4, Sébastien Blais4, François Maltais3, François Lellouche3. Cost-effectiveness of FreeO2 in patients with chronic obstructive pulmonary disease hospitalised for acute exacerbations: analysis of a pilot study in Quebec. 


Stay informed.

Subscribe to our newsletter and stay informed about the development of automated oxygen therapy and its new therapeutic perspectives.